LFMD Share Price Performance
US$3.63
-1.98 (-35.29%)
63.2% undervalued intrinsic discount
US$9.88
Fair Value
Price US$3.63
AnalystConsensusTarget US$9.88
MathieuMRoy US$30.30
AnalystLowTarget US$8.00
Fair ValueUS$9.88
Share Pricen/a
LifeMD, Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 117 Fair Values set on narratives written by author
LFMD Community Narratives
AN
Fair Value US$9.88 63.7% undervalued intrinsic discount
Expanding Care Domains And Telemedicine Will Unlock New Markets
1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
MA
Fair Value US$30.3 88.2% undervalued intrinsic discount
LifeMD is a diamond in the making
6users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$8 55.3% undervalued intrinsic discount
Intensifying Regulation And Churn Will Limit Prospects While Stability Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LifeMD is a diamond in the making
Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment.Read more
477
users have viewed this narrative6users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
MA
US$30.3
88.2% undervalued intrinsic discount
Fair Value
Profit Margin
14.71%
Future PE
31.41x
Price in 2030
US$43.86
Expanding Care Domains And Telemedicine Will Unlock New Markets
Key Takeaways Expansion into new care areas and insurance partnerships broadens market reach, reduces concentration risk, and supports stability in patient acquisition and revenue. Enhanced AI integration and the subscription-based care model improve operational efficiency, patient retention, and margin growth through automation and recurring revenue streams.Read more
247
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
AN
US$9.88
63.7% undervalued intrinsic discount
Fair Value
Profit Margin
4.92%
Future PE
48.39x
Price in 2029
US$12.48
Telemedicine Adoption And Chronic Care Expansion Will Reshape Markets
Key Takeaways Rapid adoption of new programs, AI-driven automation, and expanding insurance partnerships position LifeMD for market share gains and significantly higher growth than expected. Broadening into behavioral and women's health, combined with telemedicine trends, strengthens LifeMD's leadership and long-term recurring revenue potential.Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14.22
74.8% undervalued intrinsic discount
Fair Value
Profit Margin
5.25%
Future PE
85.71x
Price in 2029
US$17.79
Intensifying Regulation And Churn Will Limit Prospects While Stability Emerges
Key Takeaways Regulatory scrutiny, high refund rates, and customer acquisition challenges threaten margins, profitability, and the sustainability of revenue growth. High patient churn and intensifying competition may offset operational efficiencies and limit long-term earnings and margin gains.Read more
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
55.3% undervalued intrinsic discount
Fair Value
Profit Margin
4.07%
Future PE
40.34x
Price in 2028
US$9.4
Trending Discussion
Recently Updated Narratives
MA
LifeMD is a diamond in the making
Fair Value: US$30.3 88.2% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFMD: GLP-1 Focused Virtual Care Expansion Will Drive Future Weight Management Upside
Fair Value: US$9.88 63.7% undervalued intrinsic discount
19 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFMD: Weight Management Headwinds Will Set Up Telehealth Reacceleration
Fair Value: US$14.22 74.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
LifeMD, Inc. Key Details
About LFMD
- Founded
- 1994
- Employees
- 350
- CEO
- WebsiteView website
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
